Biomea Fusion reports 24 percent jump in insulin secretion in Phase 2 Icovamenib study

Biomea Fusion reports 24 percent jump in insulin secretion in Phase 2 Icovamenib study
Biomea Fusion study shows T2D gains

Biomea Fusion announced results from its Phase 2 COVALENT-111 study, showing Icovamenib led to significant improvements in patients with insulin-deficient type 2 diabetes. The therapy yielded durable reductions in HbA1c at one year, following a 12-week treatment period.

Key findings included a roughly 24 percent increase in insulin secretion and enhanced beta-cell function. These results suggest Icovamenib may offer a novel therapeutic avenue for those who are insulin-deficient. Full coverage is available via Healio.

Biomea Fusion previously highlighted plans to present Icovamenib clinical data targeting diabetes innovation at ATTD 2006, according to an earlier announcement. The company continues to focus on beta cell restoration with Icovamenib, as outlined in a statement supporting the therapy’s promise. These efforts form part of Biomea Fusion’s ongoing strategy in diabetes research.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.